Marius Weyers

About Marius Weyers

Marius is a principal associate in our global transactions team and a member of the firm’s Africa group.

Marius's work is focused on cross-border M&A, joint ventures and other investments transactions. He has more than a decade of experience advising on transactions that involve teams across various jurisdictions and different areas of specialisation, including in particular M&A transactions related to infrastructure, energy and related investments.

He is fluent in English and Afrikaans and has a working understanding of Dutch.

Recent work

• Advising CPPIB on on its long-term investment partnership with Power2X, a developer of large-scale new energy assets and infrastructure focusing on decarbonising industrial value chains and hydrogen related projects.
• Macquarie Asset Management on an initial investment of up to €175 million in SkyNRG, a player in the sustainable avaition fuel space.
• Advising HAL Investments B.V. in relation to its participation in the restructuring and acquisition of Royal IHC B.V and the proposed subsequent sale of a stake in Royal IHC B.V. to Ackermans & van Haaren and MerweOord.
• Advising The Goldman Sachs Group, Inc. on its acquisition of NN Investment Partners from NN Group N.V. for approximately €1.6 billion.
• Advising E.On (including its Dutch subsidiary Essent) on the disposal of its Dutch mid-market power and gas B2B business to Eneco.
• Advising Cargill on (i) the sale of its global malt business, including 15 facilities across four continents, to Axéréal’s malt subsidiary, Boortmalt and (ii) the disposal of its 50% interest in Alvean, a global leader in the sugar trading industry, to its Brazilian joint venture partner Copersucar.
• Advising PGGM, the Dutch pension operator and asset manager, on a joint venture with American Tower Corporation that focuses on telecommunications investment opportunities in certain European countries, including Germany and Spain.
• Advised CVC Strategic Opportunities on its €362.5m acquisition of a 50% stake in DFE Pharma, a leading global excipients manufacturer for the pharmaceutical industry.